Patents Assigned to Eligo Bioscience
  • Patent number: 11939598
    Abstract: The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: March 26, 2024
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
  • Patent number: 11905516
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 20, 2024
    Assignees: ELIGO BIOSCIENCE, INSTITUT PASTEUR
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Patent number: 11839645
    Abstract: The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: December 12, 2023
    Assignee: Eligo Bioscience
    Inventors: Antoine Decrulle, Xavier Duportet
  • Patent number: 11840695
    Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: December 12, 2023
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Patent number: 11820989
    Abstract: The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: November 21, 2023
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Publication number: 20230330157
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Application
    Filed: May 17, 2023
    Publication date: October 19, 2023
    Applicant: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11746352
    Abstract: The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding the nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering the nucleic acids of interest.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: September 5, 2023
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Xavier Duportet
  • Patent number: 11739304
    Abstract: The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: August 29, 2023
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
  • Publication number: 20230218505
    Abstract: The present invention concerns a method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein said postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing said at least one bacteriocin and/or endolysin and wherein said postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 13, 2023
    Applicant: Eligo Bioscience
    Inventors: Antoine DECRULLE, Xavier DUPORTET
  • Patent number: 11697802
    Abstract: The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: July 11, 2023
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
  • Publication number: 20230210961
    Abstract: The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
    Type: Application
    Filed: December 8, 2022
    Publication date: July 6, 2023
    Applicant: Eligo Bioscience
    Inventors: Antoine DECRULLE, Xavier DUPORTET
  • Patent number: 11690880
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: July 4, 2023
    Assignee: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11661443
    Abstract: The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 30, 2023
    Assignee: ELIGO BIOSCIENCE
    Inventor: Jesus Fernandez Rodriguez
  • Patent number: 11633348
    Abstract: A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: April 25, 2023
    Assignee: Eligo Bioscience
    Inventors: Antoine Decrulle, Xavier Duportet
  • Publication number: 20230113800
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Application
    Filed: November 3, 2022
    Publication date: April 13, 2023
    Applicant: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11617773
    Abstract: The invention relates to methods, kits and compositions for reducing the level of or eliminating Bacteroides in situ. The invention encompasses methods of preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof, comprising reducing the amount of Bacteroides sp. in the subject. The invention further encompasses methods of diagnosis of a subject as having myocarditis or dilated cardiomyopathy. The invention also encompasses compositions preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: April 4, 2023
    Assignees: Eligo Bioscience, Kantonsspital St.Gallen
    Inventors: Xavier Duportet, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig
  • Patent number: 11584781
    Abstract: The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: February 21, 2023
    Assignee: ELIGO BIOSCIENCE
    Inventors: Jesus Fernandez Rodriguez, Xavier Duportet
  • Patent number: 11584918
    Abstract: The present disclosure relates generally to methods and compositions for transferring a genetic circuit from one prokaryotic cell (“donor cell”) to another prokaryotic cell (“recipient cell” or “target cell” which are used interchangeably herein). More specifically, the present disclosure relates to prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins and the use of said donor cells in the efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding a RNA molecule or protein of interest.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 21, 2023
    Assignee: ELIGO BIOSCIENCE
    Inventors: Jesus Fernandez Rodriguez, Antonina Krawczyk, Xavier Duportet
  • Patent number: 11541106
    Abstract: The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: January 3, 2023
    Assignee: Eligo Bioscience
    Inventors: Antoine Decrulle, Xavier Duportet
  • Patent number: 11534467
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: December 27, 2022
    Assignee: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina Del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel